- Home
- PRME vs TSHA Comparison
PRME vs TSHA Comparison
Compare PRME & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- TSHA
- Stock Information
- Founded
- PRME 2019
- TSHA 2019
- Country
- PRME United States
- TSHA United States
- Employees
- PRME N/A
- TSHA N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- PRME Health Care
- TSHA Health Care
- Exchange
- PRME Nasdaq
- TSHA Nasdaq
- Market Cap
- PRME 379.1M
- TSHA 334.1M
- IPO Year
- PRME 2022
- TSHA 2020
- Fundamental
- Price
- PRME $2.97
- TSHA $1.61
- Analyst Decision
- PRME Strong Buy
- TSHA Strong Buy
- Analyst Count
- PRME 9
- TSHA 8
- Target Price
- PRME $13.13
- TSHA $6.63
- AVG Volume (30 Days)
- PRME 1.0M
- TSHA 2.1M
- Earning Date
- PRME 03-04-2025
- TSHA 02-26-2025
- Dividend Yield
- PRME N/A
- TSHA N/A
- EPS Growth
- PRME N/A
- TSHA N/A
- EPS
- PRME N/A
- TSHA N/A
- Revenue
- PRME $800,000.00
- TSHA $9,915,000.00
- Revenue This Year
- PRME N/A
- TSHA N/A
- Revenue Next Year
- PRME $477.62
- TSHA N/A
- P/E Ratio
- PRME N/A
- TSHA N/A
- Revenue Growth
- PRME N/A
- TSHA N/A
- 52 Week Low
- PRME $2.25
- TSHA $1.19
- 52 Week High
- PRME $9.77
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- PRME 53.25
- TSHA 46.14
- Support Level
- PRME $2.25
- TSHA $1.46
- Resistance Level
- PRME $3.36
- TSHA $1.76
- Average True Range (ATR)
- PRME 0.23
- TSHA 0.15
- MACD
- PRME 0.07
- TSHA 0.01
- Stochastic Oscillator
- PRME 64.41
- TSHA 39.33
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.